Loading quotes...
Forecast
The analysts' average price target is €589.87 (-0.59%). The median is €611.43 (+3.04%).
| Buy |
Â
4 |
| Hold |
Â
15 |
| Sell |
Â
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
Medpace positions itself for AI revolution in the healthcare sector
The healthcare sector is seen as the next big market for AI, with Medpace and Thermo Fisher named as holdings in a US model portfolio. The biotech sector in particular stands to benefit, as AI identifies drug candidates more quickly, predicts protein structures, and makes therapies more targeted. This could turn early drug research from lengthy testing into a data-driven selection process. » More on finanzen.net
Medpace benefits from AI potential in biotech after strong second quarter
Medpace, a global contract research organization and full-service partner for clinical trials, reported an outstanding second quarter. The company provides study design, clinical monitoring, biostatistical analysis and integrated lab services and focuses on small and mid-sized biotech firms. Medpace is seen as a potential winner from AI adoption in biotechnology, as rising numbers of clinical trials could accelerate demand growth for its services. » More on finanzen.net
Medpace: revenue rises 17.2% in Q2, net order intake climbs 28.2% and full-year guidance up to $2.89 billion
Medpace reports revenue of $707.3 million (+17.2%) for the second quarter of 2026 and a 28.2% increase in net order intake, improving the predictability of its business base. The company confirms full-year guidance of up to $2.89 billion for 2026. The news triggered a roughly 16% jump in the share price, pushing the stock toward its all-time high. » More on finanzen.net
Medpace Holdings: record revenue, but weaker order intake dampens outlook
Medpace Holdings recorded record revenue but is facing a slower-than-expected order intake. The order volume is constraining growth prospects and could soften near-term revenue momentum. Investors and clients are now watching order intake developments and management’s response to the weak demand. » More on finanzen.net
Medpace reports strong Q1 growth, stock falls on weaker order dynamics
Medpace posted Q1 2026 revenue of $706.6 million and diluted EPS of $4.28, both above analysts' expectations, but reported a quarterly book-to-bill of 0.88 and higher cancellation rates. Backlog grew slightly to $2.93 billion, yet net new business lagged last year’s peak and the 2026 outlook signals a pronounced slowdown in growth. Despite strong cash generation and stable margins, pipeline risks and customer concentration drove a roughly 24% pre-market drop. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 632.12m | 12.41% |
| Gross profit | 197.66m | 17.78% |
| Net profit | 121.36m | 28.15% |
| EBITDA | 156.69m | 22.68% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €16.62bn |
Number of shares | 27.97m |
52-week high/low | €630.48 - €338.87 |
| Dividends | No |
Beta | 1.12 |
P/E ratio | 35.62 |
PEG ratio | 1.41 |
P/B ratio | 31.24 |
P/S ratio | 6.44 |
Company profile
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.
| Name | Medpace |
| CEO | August James Troendle |
| Headquarters | Cincinnati,
oh USA |
| Website | |
| Sector | Health Care |
| Industry | Biotechnology |
| IPO | 11/08/2016 |
| Employees | 6,600 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | MEDP |
Frankfurt | 01P.F |
DĂĽsseldorf | 01P.DU |
MĂĽnchen | 01P.MU |